Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers expanding production capacity to meet rising demand

The sales performance of the company’s device was strong during the 2017 financial year.
A human eye
This second stage production expansion is expected to be completed by July 2018

Ellex Medical Lasers Limited (ASX:ELX) is increasing the production of its iTrack™ microcatheter to circa 50,000 units per annum from the current level of circa 20,000 units per annum.

The company’s illuminated microcatheters are used by physicians to perform canaloplasty for glaucoma patients.

Ellex is aiming to upgrade the production to 50,000 units per annum by expanding its manufacturing facility in Fremont, California.

In July 2017, the production capacity at Fremont was upgraded from 10,000 units per annum to 20,000 units per annum.

This second stage production expansion is expected to be completed by July 2018, by adding clean room facilities in an adjacent building and by recruiting additional technical staff.

In addition, a third stage production capacity increase to more than double the 50,000 units per annum in order to maintain supply for future demand, is currently being planned.

Ellex has witnessed material sales growth in the U.S., supported by an increase in marketing and sales spend.

Importantly, the sales performance of the Ellex’s iTrack™ technology was strong during the 2017 financial year, with sales of $8.2 million.

This represents a 41% annual growth in unit sales compared to the prior comparable period.

Sales outside of the U.S. were $3.5 million, an uplift of 49% on the prior comparable period

The expansion of the Fremont production facility will be funded from the group’s existing cash resources and earnings.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use